A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
Conditions
- Chronic Renal Failure Requiring Hemodialysis
Interventions
- BIOLOGICAL: Epoetin Hospira
Sponsor
Pfizer